In a stunning example of when treatment might be worse than the disease, a large review of Medicare records finds that older people with smallkidney tumors were much less likely to die over the next five years if doctors monitored them instead of operating right away.
On the FDA's Fast Track and in phase III testing is the company's BAY 43-9006, a small molecule RAF kinase and VEGF inhibitor that inhibits tumor growth for patients with metastatic renal cell carcinoma (advanced kidney cancer).